Profile picture

Doctor Davor Vukadinovic

Saarland University Hospital, Homburg (Germany)
Membership: FESC Member EAPCI Member HFA Member
Follow
Biography
Dr Davor Vukadinović attended School of medicine at the University of Belgrade, Serbia. He currently attends his residency at the Department of Internal Medicine and Cardiology, Angiology and Intensive Care Medicine at the Saarland University Hospital, Homburg, Germany. The main subject of his scientific interest represent adherence to the cardiovascular pharmacology, novel therapy principles in interventional cardiology and heart failure. He is a member of European Society of Cardiology.
Logo ESC

Contributor content

Efficacy and safety aspects of renal denervation in treatment of arterial hypertension: a systematic review and meta-analysis
Presentation
Efficacy and safety aspects of renal denervation in treatment of arterial hypertension: a systematic review and meta-analysis
Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis
Presentation
Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis
Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials
Presentation
Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials
Interventional patent foramen ovale closure or medical therapy only for the prevention of recurrent strokes: A meta analysis of available randomized trials
Presentation
Interventional patent foramen ovale closure or medical therapy only for the prevention of recurrent strokes: A meta analysis of available randomized trials
True rate of drug-related adverse effects on potassium homeostasis of the renin angiotensin aldosterone system inhibitors in placebo controlled trials: a meta-analysis
Presentation
True rate of drug-related adverse effects on potassium homeostasis of the renin angiotensin aldosterone system inhibitors in placebo controlled trials: a meta-analysis

ESC 365 is supported by